This company listing is no longer active
2K7 Stock Overview
TCR2 Therapeutics Inc., a clinical-stage cell therapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
TCR2 Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.44 |
| 52 Week High | US$4.00 |
| 52 Week Low | US$0.75 |
| Beta | 1.93 |
| 1 Month Change | -11.64% |
| 3 Month Change | 30.44% |
| 1 Year Change | -32.74% |
| 3 Year Change | -85.13% |
| 5 Year Change | n/a |
| Change since IPO | -88.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2K7 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -10.3% | -1.2% | -0.8% |
| 1Y | -32.7% | -15.8% | 1.0% |
Return vs Industry: 2K7 underperformed the German Biotechs industry which returned -7.6% over the past year.
Return vs Market: 2K7 underperformed the German Market which returned -7% over the past year.
Price Volatility
| 2K7 volatility | |
|---|---|
| 2K7 Average Weekly Movement | 14.5% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2K7's share price has been volatile over the past 3 months.
Volatility Over Time: 2K7's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 58 | Garry Menzel | www.tcr2.com |
TCR2 Therapeutics Inc., a clinical-stage cell therapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. Its lead product candidate is gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin-expressing solid tumors, which is in Phase 1/2 clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma and acute myeloid leukemia.
TCR2 Therapeutics Inc. Fundamentals Summary
| 2K7 fundamental statistics | |
|---|---|
| Market cap | €54.27m |
| Earnings (TTM) | -€152.33m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs 2K7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2K7 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$163.10m |
| Earnings | -US$163.10m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.15 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 2K7 perform over the long term?
See historical performance and comparison